Orph stock prediction


Orphazyme AS stock price prediction is an act of determining the future value of Orphazyme shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Orphazyme’s future price could yield a significant profit.

Stock Price Forecast

The 1 analysts offering 12-month price forecasts for Orphazyme A/S have a median target of 0.45, with a high estimate of 0.45 and a low estimate of 0.45. The median estimate represents a +780.20% increase from the last price of 0.05.


What will the onph stock price be in the future?

The ONPH (“ONPH” ) future stock price will be 135.600 USD . Will ONPH stock price crash? According to our analysis, this will not happen. Will Oncology Pharma stock price hit 100 USD price in a year?

What are analysts’price targets for Orphazyme a/s’s share price?

2 equities research analysts have issued 1 year price targets for Orphazyme A/S’s stock. Their forecasts range from $5.00 to $27.00. On average, they anticipate Orphazyme A/S’s share price to reach $16.00 in the next twelve months. This suggests a possible upside of 186.7% from the stock‘s current price.

Is oncology Pharma Inc (onph) a good long-term investment?

According to our live Forecast System, Oncology Pharma Inc stock is a very good long-term (1-year) investment*. “ONPH” stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis.

What will oncology pharma stock be worth $100 in 2026?

With a 5-year investment, the revenue is expected to be around +902.22%. Your current $100 investment may be up to $1002.22 in 2026. Note: due to the specific nature of Oncology Pharma stock, the prediction can be significantly excessive / unrealistic!


Is Orph a good stock to buy?

Our overall hedge fund sentiment score for ORPH is 27.8. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score.

Does HCMC stock have a future?

Our Ai stock analyst implies that there will be a negative trend in the future and the HCMC shares are not a good investment for making money. Since this share has a negative outlook we recommend looking for other projects instead to build a portfolio.

Will Osat stock go up?

Based on our forecasts, a long-term increase is expected, the “OSAT” stock price prognosis for 2027-03-23 is 9.211 USD. With a 5-year investment, the revenue is expected to be around +246.27%. Your current $100 investment may be up to $346.27 in 2027.

Is HCMC a good stock investment?

According to investors, the stock of HCMC has a lot of potential upsides. Users are switching to healthy items as the company keeps developing creative products. Any substantial patent court victory could pay off handsomely for speculators in HCMC.

Will HCMC bounce back?

Even without recovering 2021’s highs, an upside move from the current level can deliver superb returns on the stock if the recovery is initiated. This in itself would represent a 150% bounce from current levels. Above this level, 0.007 and 0.001 could form additional targets to the north.

What is HCMC price target?

$42,000,000.00Stock Price Target HCMCHigh$42,000,000.00Median$42,000,000.00Low$42,000,000.00Average$42,000,000.00Current Price$0.00

What is Osat?

OSAT stands for Outsourced Semiconductor Assembly and Test. This is a third-party service that suppliers around the world offer, which consists, as the name implies, of semiconductor assembly, packaging and testing of ICs (Integrated Circuits).

Why was HCMC stock so high?

HCMC stock was recently boosted by renewed interest in a vaping device patent infringement lawsuit against Philip Morris International (NYSE:PM). That lawsuit was announced in November of last year, but picked up investing interest again following a Jan. 26, 2021, post on subreddit r/WallStreetBets.

What is HCMC lawsuit?

The big story on HCMC is its patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in connection with their product known and marketed as “IQOS®.” The lawsuit was filed in the United States District Court for the Northern District of Georgia.

Who owns HCMC stock?

Top 10 Owners of Healthier Choices Management CorpStockholderStakeShares ownedFineMark National Bank & Trust (I…0.07%231,315,488Virtue Capital Management LLC0.00%2,071,428Elmwood Wealth Management, Inc.0.00%0Advisors Management Group, Inc.0.00%25,0005 more rows

Is ORPH stock a buy right now?

2 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Orphazyme A/S in the last twelve months. There are currently 1 se…

Who are Orphazyme A/S’s key executives?

Orphazyme A/S’s management team includes the following people: Mr. Anders Fink Vadsholt M.B.A. , M.Sc., MBA, Chief Financial Officer (Age 52, Pa…

Who are some of Orphazyme A/S’s key competitors?

Some companies that are related to Orphazyme A/S include Eliem Therapeutics (ELYM) , Immunic (IMUX) , Checkpoint Therapeutics (CKPT) , Adagene…

When did Orphazyme A/S IPO?

(ORPH) raised $100 million in an IPO on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cow…

What is Orphazyme A/S’s stock symbol?

Orphazyme A/S trades on the NASDAQ under the ticker symbol “ORPH.”

Who are Orphazyme A/S’s major shareholders?

Orphazyme A/S’s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%…

Which institutional investors are selling Orphazyme A/S stock?

ORPH stock was sold by a variety of institutional investors in the last quarter, including HAP Trading LLC, Cutler Group LP, and Group One Trading…

Which institutional investors are buying Orphazyme A/S stock?

ORPH stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC.

How much money does Orphazyme A/S make?

Orphazyme A/S (NASDAQ:ORPH) has a market capitalization of $0.00.

Analyst Price Target Consensus

Sign-up to receive the latest news and ratings for ORPH and its competitors with MarketBeat’s FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target.

ONPH Target Price

ONPH price target in 14 days: 7.587 USD* upside and 4.783 USD* downside. (Highest and lowest possible predicted price in a 14 day period)

Oncology Pharma Inc ( ONPH ) Stock Market info

Recommendations: Buy or sell Oncology Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You’ll find the Oncology Pharma share forecasts, stock quote and buy / sell signals below.


Leave a Comment